Concepedia

Howard L. Kaufman

HL

Statistics

Publications

5

Citations

3.3K

H-Index

5

Active since

2002

Affiliations

Amgen (United States)(Current)

Huntsman Cancer Institute

Royal Marsden Hospital

Amgen (United Kingdom)

Rutgers Cancer Institute

Howard L. Kaufman is an author at Amgen (United States) specializing in cancer immunology, cancer immunotherapy, and oncology.

ORCID

Publications per year

2002–2019

5

Publications

5

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio et al. · Journal of Clinical Oncology · 2015 · 2.6K citations · Full text

, , +17

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Robert H.I. Andtbacka, Frances A. Collichio, Kevin J. Harrington et al. · Journal for ImmunoTherapy of Cancer · 2019 · 438 citations · Full text

, , +17

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial

Kevin J. Harrington, Robert H.I. Andtbacka, Frances A. Collichio et al. · OncoTargets and Therapy · 2016 · 101 citations · Full text

, , +17

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

Howard L. Kaufman, Thomas Amatruda, Tony Reid et al. · Journal for ImmunoTherapy of Cancer · 2016 · 99 citations · Full text

, , +17

Uterine rupture with the use of PGE2 vaginal inserts for labor induction in women with previous cesarean sections.

Donald R. Taylor, Andrea Doughty, Howard L. Kaufman et al. · PubMed · 2002 · 38 citations

, , +17

1–5 of 5